Title: The Therapeutic Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure

Abstract:

Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. The conventional treatment of POF remains a limited success rate. Therefore, an innovative treatment strategy like the regeneration of premature ovaries by using human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To summarize all the theoretical frameworks for additional research and clinical trials, this review article highlights all the results, pros, and cons of the hUC-MSCs used to treat POF. So far, the data shows promising results regarding the treatment of POF using hUC-MSCs. Several properties like relatively low immunogenicity, multipotency, multiple origins, affordability, convenience in production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good choice for treating basic POF. It has been reported that hUC-MSCs impact and enhance all stages of injured tissue regeneration by concurrently stimulating numerous pathways in a paracrine manner, which are involved in the control of ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. Furthermore, some studies demonstrated that stem cell treatment could lead to hormone-level restoration, follicular activation, and functional restoration of the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for the treatment of POF encourage researchers for further clinical trials, which will overcome the ongoing challenges and make this treatment strategy applicable to the clinic shortly.

Biography:

Greene is a residency and fellowship-trained orthopedic surgeon who has shifted completely into business. He started a healthcare internet marketing company, US Lead Network, that helps medical and dental practices acquire patients on the web in a pay-for-performance manner. The company is now using Artificial Intelligence for marketing which is lowering the cost per lead substantially. He has written two books on Healthcare Internet Marketing that are available for purchase on Amazon. He has been featured as a Top 20 Expert Author by Ezines.com, the top article directory site in the world. Out of over 470,000 authors, Greene ranks #15 as an Expert Author and #1 in the Pain Management category. He also started a regenerative medicine company, R3 Stem Cell, that offers marketing, an IRB-approved protocol, and top products for practices nationwide. R3 offers stem cell training courses that are second to none at https://stemcelltrainingcourse.org

Title: Breast Cancer Treatment, nanoparticle encapsulated doxorubicin and Drug Safety

Abstract:

Breast cancer is the most common cancer in women worldwide. It is also the principal cause of death from cancer among women globally. Despite the high incidence rates, in Western countries, 89% of women diagnosed with breast cancer are still alive 5 years after their diagnosis, which is due to detection and treatment. Breast cancer incidence has been increasing. In 2015, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 60,290 new cases of non-invasive (in situ) breast cancer. About 2,350 new cases of invasive breast cancer are expected to be diagnosed in men in 2015. A man’s lifetime risk of breast cancer is about 1 in 1,000. Breast cancer incidence rates in the U.S. began decreasing in the year 2000, after increasing for the previous two decades. They dropped by 7% from 2002 to 2003 alone. One theory is that this decrease was partially due to the reduced use of hormone replacement therapy (HRT) by women after the results of a large study called the Women’s Health Initiative were published in 2002. These results suggested a connection between HRT and increased breast cancer risk. About 40,290 women in the U.S. are expected to die in 2015 from breast cancer, though death rates have been decreasing since 1989. Women under 50 have experienced larger decreases. These decreases are thought to be the result of treatment advances, earlier detection through screening, and increased awareness. White women are slightly more likely to develop breast cancer than African-American women. However, in women under 45, breast cancer is more common in African-American women than in white women. Overall, African-American women are more likely to die of breast cancer. The risk of developing and dying from breast cancer is lower in Asian, Hispanic, and Native-American women. About 5-10% of breast cancers can be linked to gene mutations (abnormal changes) inherited from one’s mother or father. Mutations of the BRCA1 and BRCA2 genes are the most common. On average, women with a BRCA1 mutation have a 55-65% lifetime risk of developing breast cancer. For women with a BRCA2 mutation, the risk is 45%. Breast cancer that is positive for the BRCA1 or BRCA2 mutations tends to develop more often in younger women. Increased ovarian cancer risk is also associated with these genetic mutations. In men, BRCA2 mutations are associated with a lifetime breast cancer risk of about 6.8%; BRCA1 mutations are a less frequent cause of breast cancer in men.  All drugs for breast cancer treatment developed and on the market cause mild to several side effects, and the safety, pharmacovigilance, signal detection, and risk management of breast cancer drugs are difficult to report and manage.  A series of challenges of breast cancer therapy and drug safety will be reported and discussed at the meeting along with liposomal nanoparticle encapsulated doxorubicin.

Biography:

Ashok Srivastava is the Chief Medical Officer of Trans Atlantic Therapeutics  Oncology,   He was the Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New Jersey, USA. He has more than 15 years of experience in drug development, medical affairs, and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of  Hematology, Oncology, and radiopharmaceutical drugs in the USA, EU, and Japan.  He is the leader in Cancer Drug Development  Worldwide large and complex Phase 3 Clinical Trials in many countries.  He contributed to 21-INDs and 7-NDAs of Cancer Drugs, the acquisition /merger of a company and drug for more than $300 million. He received his clinical, and medical training  & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center,  Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; the Academy of Medical Sciences, Czechoslovakia; the School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA.

Title: Suicide Ideation and Attempts in Cancer Research Institute (CRI) of the California South University (CSU) before and during COVID-19 Pandemic

Abstract:

Weather adjustments affect planet groups, residing beings, humans, inclusive of their lives, rights, (system of people making, selling, and shopping for matters), housing, shifting (from one place to some other), and both bodily and mental health. Geo-mental health care is a new manage/area of take a look at in the field of mental fitness care reading the (connecting factor/manner of interacting with something) among distinctive geo-political factors which includes (associated with wherein mountains, rivers, towns, and so forth., are positioned), political, money-based, commercial and cultural (things that decide other things) which have an effect on (community of human beings/all top humans in the global) and mental health care: it affords an (interested in the whole or the completeness of something) summary on global troubles which include climate modifications, poorness, public health and (how clean some thing is to get to, use, or understand) to fitness care. It identifies (associated with how land, rivers, etc. affect a country's policies and relationships) factors and their results at the international and national degrees, as well as thinks about/believes the politics of climate modifications and poorness inside this huge picture. This paper then introduces the Kindness, sturdy and self-confident motion, (smart approaches of doing matters), and (occasion(s) or object(s) that show something) weak spot (that might be used to hurt a person or something) Index (CAPE-VI) as a international overseas coverage index: CAPE-VI calculates how money from other nations should be prioritized for international locations which might be at chance or already idea about/believed to be sensitive and breakable.

Biography:

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Distinguished Professor and Academic Tenure of Chemistry and also Enrico Fermi Distinguished Chair in Molecular Spectroscopy at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA.

Title: Stem Cells in Bone Repair and Regeneration

Abstract:

Bones normally function to provide both mechanical and locomotion supports in the body. They are highly specialized connective tissues that are characterized by mineralized extracellular components, which provide both rigidity and strength to bones. Stem cells hold great potentials for both the repair and regeneration of different tissue types, including bone tissues. The future use of stem cell therapy is promising for developing regenerative medicine approaches to treat disorders and diseases in a wide range of tissues such as cartilages and bones. Data have been accumulated recently on the application of different stem cell types in bone repair, regeneration, and disorders. In this article, we briefly describe bone structure and review research progress and recently accumulated data on stem cell differentiation into osteoblasts as well as discuss the contributions of stem cell types to bone and cartilage repair, regeneration, and disease.

Biography:

Ahmed Hashash has completed his Ph.D. from Manchester University, UK. He is a fellow of the California Institute of Regenerative Medicine (CIRM) and New York University Medical School (MSSM), USA. Prof. Ahmed Hashash worked as a senior biomedical research scientist at Mount Sinai School of Medicine of New York University and Children’s Hospital Los Angeles. He was Assistant Professor and Principal Investigator of Stem Cell & Regenerative Medicine at Keck School of Medicine and Ostrow School of Dentistry of The University of Southern California, USA. In 2016, Prof. Hashash joined The University of Edinburgh, Edinburgh Medical School-Zhejiang International Campus, (ZJU) as a Tenure-Track Associate Professor and Senior Principal Investigator of Biomedicine, Stem Cell & Regenerative Medicine. He is also an adjunct Professor at the School of Basic Medical Science and School of Medicine, at Zhejiang University.

Title: Bridging the Gap: AI-Driven Solutions for Dental Tissue Regeneration

Abstract:

Dental tissue loss presents a major challenge in oral health. Traditional treatments offer limited solutions, lacking true regenerative potential. Artificial intelligence (AI) is emerging as a powerful tool in dental tissue engineering, offering the potential to revolutionize how we treat dental defects. This paper explores the convergence of AI and dental tissue engineering, highlighting its potential to bridge the gap in regeneration. We discuss limitations of current methods and how AI can address these challenges through: NL Journal of Dentistry and Oral Sciences Bridging the Gap: AI-Driven Solutions for Dental Tissue Regeneration Dental tissue engineering (DTE) offers a revolutionary approach to treating tooth loss and oral defects by utilizing biomaterials and cells to regenerate lost tissues. However, optimizing this process requires tackling complex challenges in material design, cell behavior prediction, and treatment personalization. This is where Artificial Intelligence (AI) emerges as a powerful tool, holding immense potential to revolutionize the field of DTE. Predicting Cell Behavior: Understanding how different cell types, particularly stem cells, respond to various stimuli within the biomaterial scaffold is crucial for successful tissue regeneration. AI algorithms excel at analyzing complex biological data. Studies by [2] showcase how AI can analyze cell responses to biomaterial properties and external factors like growth factors. This predictive power allows researchers to tailor the biomaterial design and culture conditions to achieve the desired cell behavior, ensuring the formation of functional dental structures. The integration of AI holds immense potential for personalized regenerative therapies, improved treatment outcomes, and a new era of dental health.

Biography:

Omid Panahi was graduated from Centro Escolar University in 2013 in the field of Doctor of Dental Medicine (DMD), and MSc Oral and Maxillofacial Surgery at Yeditepe University, Istanbul, Turkey. He has published more than 45 papers in reputed journals and 6 books and  has been serving as an Editorial Board Member of ISI journals.